<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299975</url>
  </required_header>
  <id_info>
    <org_study_id>PID-001</org_study_id>
    <nct_id>NCT00299975</nct_id>
  </id_info>
  <brief_title>A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation</brief_title>
  <official_title>A Randomized Controlled Trial of Chinese Herbal Medicine in Three-dose Regimen for the Treatment of Functional Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hong Kong Baptist University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hong Kong Baptist University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but
      treatment for this condition in conventional medicine is suboptimal. Complementary and
      alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by
      patients with FC, but there is little research evidence about these commonly used CHM. The
      purpose of the study is evaluate the efficacy and safety of CHM, as well as determining the
      optimal dosage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional constipation (FC) is a common complaint in clinical practice, with the estimated
      prevalence 14.3% in Hong Kong, as nearly affecting 1 million Hong Kong People in different
      extent. It is comparable with western population, which is 15% in North America. By the
      definition of Rome II criteria, FC comprises a group of functional disorders, which presents
      as persistent difficult, infrequent or seemingly incomplete defecation.

      Constipation is often perceived to be benign, easily treated condition with short-term
      treatment being relatively straightforward. However, the fact is the management of FC is
      perplexed as some subjects complain of constipation more than decade. Moreover, chronic
      constipation can develop into more serious bowel complaints, such as faecal impaction,
      incontinence and bowel perforations. There is also accumulating evidence shown that
      constipated subjects have significantly higher anxiety and depression scores and lower
      quality of life. Therefore, the demand of effective agents to normalize bowel function is
      extremely large.

      Conventional treatment for constipation mainly relies on dietary fibre and laxatives.
      Although there is no credible evidence that any serious problem is associated with their
      prolonged use, the treatment of it has been suboptimal. First, a recent systematic review
      pointed out that there were paucity of trials for many commonly used agents, therefore, their
      use might not be well validated. Second, many patients with severe constipation do not
      respond adequately or lose of effectiveness after a short period of time. Third, many
      patients who intake dietary fibre complain of flatulence, distension, bloating and poor
      taste. As a result, the compliance is low as about 50%. Fourth, the use of osmotic laxatives,
      such as polyethylene glycol, become increasingly popular due to fewer side effects and better
      taste, however, the prices are much more expensive than other medications. Many constipation
      sufferers seek help from alternative medicine, especially from Chinese herbal medicine. For
      example, according to a telephone survey in Hong Kong, more than 85% of constipated subjects
      seek for coping strategies, such as asking for medical consultations, taking prescribed
      medicine and seeking for alternative therapy, involving Chinese medicine.

      Traditional Chinese medicine (TCM) is particularly attractive as their effectiveness in
      treating functional disorders and retaining balance of body functions. The CHM used in study
      is derived from classic text of Chinese medicine (Shang Han Lun, Discussion of Cold-induced
      Disorders), which can &quot;moisten the intestines, drain heat, promote the movement of qi and
      unblock the bowel&quot;.

      It is well known that randomized controlled trial (RCT) is the gold standard to test the
      efficacy of intervention, thus in this project, we attempt to follow the basic requirements
      of RCT to testify the efficacy and safety of CHM on FC, as well as to determine the optimal
      dosage. We believe such study will benefit the advancement of CHM, or even as the foundation
      of research study in future.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder for Complete Spontaneous Bowel Movement (CSBM)</measure>
    <time_frame>Week3-10</time_frame>
    <description>Participants with a mean increase of CSBM&gt;=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder for Complete Spontaneous Bowel Movement (CSBM)</measure>
    <time_frame>Week11-18</time_frame>
    <description>Participants with a mean increase of CSBM&gt;=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Movement</measure>
    <time_frame>Baseline(Week1-2), Within treatment(Week3-10) &amp; Within follow-up(Week11-18)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Spontaneous Bowel Movement (CSBM)</measure>
    <time_frame>Baseline(Week1-2), Within treatment(Week3-10) &amp; Within follow-up(Week11-18)</time_frame>
    <description>CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Symptoms Improvement</measure>
    <time_frame>Week6, 10 &amp; 18</time_frame>
    <description>Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply &quot;improved&quot; for score 4 to 6, &quot;same&quot; for score 3 or &quot;worse&quot; for score 0 to 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Constipation</measure>
    <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
    <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensation of Straining</measure>
    <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
    <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incomplete of Evacuation</measure>
    <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
    <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensation of Bloating</measure>
    <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
    <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensation of Abdominal Pain/Cramping</measure>
    <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
    <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Passing of Gas</measure>
    <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
    <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects (e.g. Renal and Liver Function Tests)</measure>
    <time_frame>pre-treatment &amp; post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Level</measure>
    <time_frame>Pre-treatment(Week2) &amp; Post-treatment(Week10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Creatinine Level</measure>
    <time_frame>Pre-treatment(Week2) &amp; Post-treatment(Week10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Glutamic Pyruvic Transaminase(SGPT) Level</measure>
    <time_frame>Pre-treatment(Week2) &amp; Post-treatment(Week10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Glutamic Oxaloacetic Transaminase(SGOT) Level</measure>
    <time_frame>Pre-treatment(Week2) &amp; Post-treatment(Week10)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>MaZiRenWan (MZRW) Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MaZiRenWan (MZRW) Median dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MaZiRenWan (MZRW) High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MaZiRenWan (MZRW) Low dose</intervention_name>
    <description>Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks</description>
    <arm_group_label>MaZiRenWan (MZRW) Low dose</arm_group_label>
    <other_name>Hemp Seed Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MaZiRenWan (MZRW) Median dose</intervention_name>
    <description>Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks</description>
    <arm_group_label>MaZiRenWan (MZRW) Median dose</arm_group_label>
    <other_name>Hemp Seed Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MaZiRenWan (MZRW) High dose</intervention_name>
    <description>Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks</description>
    <arm_group_label>MaZiRenWan (MZRW) High dose</arm_group_label>
    <other_name>Hemp Seed Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of functional constipation with Rome II criteria

          -  General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale

          -  Complete spontaneous bowel movementâ‰¦2 movements per week

        Exclusion Criteria:

          -  Anti-diarrhoeal therapy

          -  Drug-induced constipation

          -  Medical history of important bowel pathology, such as inflammatory bowel disease,
             congenital or acquired megacolon / megarectum

          -  Medical history of previous abdominal surgery

          -  Taking chronic medications that contain any kind of herbs, mineral, or specific
             vitamin supplements

          -  Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes
             mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases

          -  History of laxative abuse

          -  History of allergy to Chinese herbal medicine

          -  Psychiatric or addictive disorders

          -  Pregnancy or breast-feeding

          -  Any other serious diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ZhaoXiang Bian, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hong Kong Baptist University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hong Kong Baptist University Chinese Medicine Clinic</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21045817</url>
    <description>Abstract</description>
  </link>
  <results_reference>
    <citation>Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol. 2011 Jan;106(1):120-9. doi: 10.1038/ajg.2010.305. Epub 2010 Nov 2.</citation>
    <PMID>21045817</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2006</study_first_submitted>
  <study_first_submitted_qc>March 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2006</study_first_posted>
  <results_first_submitted>August 2, 2011</results_first_submitted>
  <results_first_submitted_qc>November 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2011</results_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hong Kong Baptist University</investigator_affiliation>
    <investigator_full_name>ZhaoXiang Bian</investigator_full_name>
    <investigator_title>Professor, Director of Clinical Division</investigator_title>
  </responsible_party>
  <keyword>Randomized Controlled Trials</keyword>
  <keyword>Medicine, Chinese Traditional</keyword>
  <keyword>Medicine, Herbal</keyword>
  <keyword>Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All constipated patients (aged 18-65) who presented to the Chinese Medicine Clinics of School of Chinese Medicine, Hong Kong Baptist University from October 2006 to May 2007 were refered.</recruitment_details>
      <pre_assignment_details>177 patients were screened; of these 80 patients were excluded due to not meeting inclusion criteria (68 cases), refused to participate (6 cases) and lost to follow up (6 cases).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Group</title>
          <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Median Dose Group</title>
          <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>High Dose Group</title>
          <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Allocated Intervention</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Group</title>
          <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Median Dose Group</title>
          <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>High Dose Group</title>
          <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="9.8"/>
                    <measurement group_id="B2" value="38.8" spread="9.9"/>
                    <measurement group_id="B3" value="36.1" spread="9.2"/>
                    <measurement group_id="B4" value="36.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of constipation</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="8.5"/>
                    <measurement group_id="B2" value="13.7" spread="10.0"/>
                    <measurement group_id="B3" value="15.0" spread="10.9"/>
                    <measurement group_id="B4" value="13.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bowel Movement</title>
          <units>movements per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" spread="1.5"/>
                    <measurement group_id="B2" value="3.1" spread="1.4"/>
                    <measurement group_id="B3" value="4.7" spread="4.1"/>
                    <measurement group_id="B4" value="3.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Complete Spontaneous Bowel Movement (CSBM)</title>
          <description>CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
          <units>movements per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" spread="0.6"/>
                    <measurement group_id="B2" value="0.5" spread="0.7"/>
                    <measurement group_id="B3" value="0.5" spread="0.7"/>
                    <measurement group_id="B4" value="0.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of days taking rescue therapy</title>
          <description>Any medications, including laxatives, enemas and Chinese herbal medicine, for facilitating bowel movements.</description>
          <units>days per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="2.8"/>
                    <measurement group_id="B2" value="2.4" spread="3.3"/>
                    <measurement group_id="B3" value="2.2" spread="3.2"/>
                    <measurement group_id="B4" value="2.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severity of Constipation</title>
          <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="1.1"/>
                    <measurement group_id="B2" value="4.1" spread="1.3"/>
                    <measurement group_id="B3" value="4.3" spread="1.5"/>
                    <measurement group_id="B4" value="4.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Responder for Complete Spontaneous Bowel Movement (CSBM)</title>
        <description>Participants with a mean increase of CSBM&gt;=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
        <time_frame>Week3-10</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder for Complete Spontaneous Bowel Movement (CSBM)</title>
          <description>Participants with a mean increase of CSBM&gt;=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <method_desc>Chi-squared test from Crosstabs analysis.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder for Complete Spontaneous Bowel Movement (CSBM)</title>
        <description>Participants with a mean increase of CSBM&gt;=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
        <time_frame>Week11-18</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder for Complete Spontaneous Bowel Movement (CSBM)</title>
          <description>Participants with a mean increase of CSBM&gt;=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <method_desc>Chi-squared test from Crosstabs analysis.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Movement</title>
        <time_frame>Baseline(Week1-2), Within treatment(Week3-10) &amp; Within follow-up(Week11-18)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Movement</title>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>movements per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.5"/>
                    <measurement group_id="O2" value="3.1" spread="1.4"/>
                    <measurement group_id="O3" value="4.7" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk3-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.7"/>
                    <measurement group_id="O2" value="4.8" spread="1.8"/>
                    <measurement group_id="O3" value="6.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk11-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.6"/>
                    <measurement group_id="O2" value="3.5" spread="1.2"/>
                    <measurement group_id="O3" value="5.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Spontaneous Bowel Movement (CSBM)</title>
        <description>CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
        <time_frame>Baseline(Week1-2), Within treatment(Week3-10) &amp; Within follow-up(Week11-18)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Spontaneous Bowel Movement (CSBM)</title>
          <description>CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>movements per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.6"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                    <measurement group_id="O3" value="0.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week3-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.4"/>
                    <measurement group_id="O2" value="1.6" spread="1.5"/>
                    <measurement group_id="O3" value="2.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week11-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.5"/>
                    <measurement group_id="O2" value="1.0" spread="1.2"/>
                    <measurement group_id="O3" value="1.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Symptoms Improvement</title>
        <description>Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply &quot;improved&quot; for score 4 to 6, &quot;same&quot; for score 3 or &quot;worse&quot; for score 0 to 2.</description>
        <time_frame>Week6, 10 &amp; 18</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Symptoms Improvement</title>
          <description>Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply &quot;improved&quot; for score 4 to 6, &quot;same&quot; for score 3 or &quot;worse&quot; for score 0 to 2.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week6-Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6-Same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6-Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10-Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10-Same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10-Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week18-Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week18-Same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week18-Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <method_desc>Chi-squared test from Crosstabs analysis was implemented between three treatment groups in each time frame.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Constipation</title>
        <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
        <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Constipation</title>
          <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" spread="1.07"/>
                    <measurement group_id="O2" value="4.06" spread="1.32"/>
                    <measurement group_id="O3" value="4.25" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="1.87"/>
                    <measurement group_id="O2" value="2.03" spread="1.84"/>
                    <measurement group_id="O3" value="2.03" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="1.88"/>
                    <measurement group_id="O2" value="2.06" spread="1.76"/>
                    <measurement group_id="O3" value="2.06" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="1.91"/>
                    <measurement group_id="O2" value="2.91" spread="1.92"/>
                    <measurement group_id="O3" value="2.38" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensation of Straining</title>
        <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
        <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensation of Straining</title>
          <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="1.06"/>
                    <measurement group_id="O2" value="3.53" spread="1.61"/>
                    <measurement group_id="O3" value="3.78" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="1.79"/>
                    <measurement group_id="O2" value="1.84" spread="1.73"/>
                    <measurement group_id="O3" value="2.16" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="1.92"/>
                    <measurement group_id="O2" value="2.06" spread="1.70"/>
                    <measurement group_id="O3" value="1.94" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="1.86"/>
                    <measurement group_id="O2" value="2.78" spread="1.88"/>
                    <measurement group_id="O3" value="2.34" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incomplete of Evacuation</title>
        <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
        <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incomplete of Evacuation</title>
          <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" spread="1.41"/>
                    <measurement group_id="O2" value="3.5" spread="1.63"/>
                    <measurement group_id="O3" value="3.97" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="1.87"/>
                    <measurement group_id="O2" value="2.59" spread="1.66"/>
                    <measurement group_id="O3" value="2.59" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="1.91"/>
                    <measurement group_id="O2" value="2.63" spread="1.64"/>
                    <measurement group_id="O3" value="2.66" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="1.83"/>
                    <measurement group_id="O2" value="2.94" spread="1.70"/>
                    <measurement group_id="O3" value="2.50" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensation of Bloating</title>
        <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
        <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensation of Bloating</title>
          <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="1.90"/>
                    <measurement group_id="O2" value="2.75" spread="1.92"/>
                    <measurement group_id="O3" value="3.28" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="1.91"/>
                    <measurement group_id="O2" value="1.84" spread="1.63"/>
                    <measurement group_id="O3" value="1.91" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="1.85"/>
                    <measurement group_id="O2" value="1.63" spread="1.66"/>
                    <measurement group_id="O3" value="1.75" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="1.69"/>
                    <measurement group_id="O2" value="2.19" spread="1.86"/>
                    <measurement group_id="O3" value="1.94" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensation of Abdominal Pain/Cramping</title>
        <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
        <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensation of Abdominal Pain/Cramping</title>
          <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.24"/>
                    <measurement group_id="O2" value="1.12" spread="1.29"/>
                    <measurement group_id="O3" value="1.59" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.27"/>
                    <measurement group_id="O2" value="1.03" spread="1.31"/>
                    <measurement group_id="O3" value="1.50" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.98"/>
                    <measurement group_id="O2" value="1.09" spread="1.20"/>
                    <measurement group_id="O3" value="1.47" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.92"/>
                    <measurement group_id="O2" value="0.91" spread="1.25"/>
                    <measurement group_id="O3" value="0.84" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Passing of Gas</title>
        <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
        <time_frame>Baseline(Week2), Within treatment(Week6), End of treatment(Week10) &amp; End of follow-up(Week18)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Passing of Gas</title>
          <description>It was a 7-point ordinal scale from 0=not at all to 6=very severe.</description>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="1.70"/>
                    <measurement group_id="O2" value="2.59" spread="1.43"/>
                    <measurement group_id="O3" value="3.34" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="1.49"/>
                    <measurement group_id="O2" value="1.97" spread="1.49"/>
                    <measurement group_id="O3" value="2.44" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="1.24"/>
                    <measurement group_id="O2" value="2.06" spread="1.27"/>
                    <measurement group_id="O3" value="2.38" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.19"/>
                    <measurement group_id="O2" value="2.19" spread="1.36"/>
                    <measurement group_id="O3" value="2.53" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects (e.g. Renal and Liver Function Tests)</title>
        <time_frame>pre-treatment &amp; post-treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Urea Level</title>
        <time_frame>Pre-treatment(Week2) &amp; Post-treatment(Week10)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Urea Level</title>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="1.23"/>
                    <measurement group_id="O2" value="4.54" spread="1.12"/>
                    <measurement group_id="O3" value="4.31" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="1.18"/>
                    <measurement group_id="O2" value="4.41" spread="0.94"/>
                    <measurement group_id="O3" value="4.30" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Paired-Samples T Test</method>
            <method_desc>Paired-Samples T Test was implemented between pre-treatment (Wk2) and post-treatment (Wk10) of each treatment group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Creatinine Level</title>
        <time_frame>Pre-treatment(Week2) &amp; Post-treatment(Week10)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Creatinine Level</title>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>Î¼mol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.81" spread="13.22"/>
                    <measurement group_id="O2" value="58.00" spread="15.23"/>
                    <measurement group_id="O3" value="57.38" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.81" spread="10.17"/>
                    <measurement group_id="O2" value="60.06" spread="17.27"/>
                    <measurement group_id="O3" value="58.09" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Paired-Samples T Test</method>
            <method_desc>Paired-Samples T Test was implemented between pre-treatment (Wk2) and post-treatment (Wk10) of each treatment group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Glutamic Pyruvic Transaminase(SGPT) Level</title>
        <time_frame>Pre-treatment(Week2) &amp; Post-treatment(Week10)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Glutamic Pyruvic Transaminase(SGPT) Level</title>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.38" spread="6.95"/>
                    <measurement group_id="O2" value="32.78" spread="5.33"/>
                    <measurement group_id="O3" value="34.06" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.44" spread="8.99"/>
                    <measurement group_id="O2" value="34.06" spread="6.67"/>
                    <measurement group_id="O3" value="34.16" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Paired-Samples T Test</method>
            <method_desc>Paired-Samples T Test was implemented between pre-treatment (Wk2) and post-treatment (Wk10) of each treatment group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Glutamic Oxaloacetic Transaminase(SGOT) Level</title>
        <time_frame>Pre-treatment(Week2) &amp; Post-treatment(Week10)</time_frame>
        <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Group</title>
            <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Median Dose Group</title>
            <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Group</title>
            <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Glutamic Oxaloacetic Transaminase(SGOT) Level</title>
          <population>Statistical analysis was performed on the population being randomized and receiving allocated intervention. Missing values were imputed by the method of last observation carried forward.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.50" spread="5.01"/>
                    <measurement group_id="O2" value="18.28" spread="4.30"/>
                    <measurement group_id="O3" value="19.44" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.69" spread="5.04"/>
                    <measurement group_id="O2" value="19.09" spread="5.08"/>
                    <measurement group_id="O3" value="19.09" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Paired-Samples T Test</method>
            <method_desc>Paired-Samples T Test was implemented between pre-treatment (Wk2) and post-treatment (Wk10) of each treatment group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks</time_frame>
      <desc>Within the whole study period</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Group</title>
          <description>MaZiRenWan (MZRW) 2.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Median Dose Group</title>
          <description>MaZiRenWan (MZRW) 5.0g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>High Dose Group</title>
          <description>MaZiRenWan (MZRW) 7.5g/sachet Patients were instructed to dissolve a sachet of granules in 150 ml of hot water; they took this solution orally twice daily for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Other</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain/cramping or bloating</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper gastro-intestinal discomfort</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increase body odor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance of menstruation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Puffy face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Zhao-xiang Bian</name_or_title>
      <organization>Hong Kong Baptist University</organization>
      <phone>(852) 3411 2905</phone>
      <email>bzxiang@hkbu.edu.hk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

